$34.48Bn Growth for Immunodiagnostics Market Share to Hit 7.6% CAGR with Chemiluminescence Immunoassays (CLIA) Segment Driving Growth During 2022-2030 | The Insight Partners


North America held the largest market share of the global immunodiagnostics market, which was valued at US$ 9,772.80 million in 2022, with a CAGR of 7.5% during 2022-2030; due to rising prevalence of infectious diseases and the growing use of point-of-care immunodiagnostics.

Pune, India, July 20, 2023 (GLOBE NEWSWIRE) — According to Recently Published Report by The Insight Partners, “Immunodiagnostics Market Size Report and Forecast to 2030 – COVID-19 Impact and Global Analysis by Product, Clinical Indication, End User, and Geography”; the market size is expected to grow to $34.48 billion by 2030 from $19.21 billion in 2022; it is estimated to register a CAGR of 7.6% from 2022 to 2030. By product, the chemiluminescence immunoassays (CLIA) segment is anticipated to register the highest CAGR during 2022-2030, and is further segmented into vitamin D assay, HIV detection, HIV AG/AB combo assay, and others.


Download Sample Pages: https://www.theinsightpartners.com/sample/TIPRE00003722

Global Immunodiagnostics Market Report Scope, Segmentations, Regional & Country Scope:

Report Coverage Details
Market Size Value in USD 19.21 Billion in 2022
Market Size Value by USD 34.48 Billion by 2030
Growth rate CAGR of 7.6% from 2022 to 2030
Forecast Period 2022-2030
Base Year 2022
No. of Pages 270
No. of Tables 166
No. of Charts & Figures 98
Historical data available Yes
Segments covered Product, Clinical Indication, End User, and Geography

Global Immunodiagnostics Market: Competitive Landscape and Key Developments
Abbott Laboratories, F. Hoffmann-La Roche Ltd, DiaSorin SpA, Danaher Corp, Thermo Fisher Scientific Inc, PerkinElmer Inc, Shenzhen Mindray Bio-Medical Electronics Co Ltd, bioMerieux SA, Svar Life Science AB, and Siemens Healthineers AG are a few key companies operating in the immunodiagnostics market. These companies adopt product innovation strategies to meet evolving customer demands, which allows them to maintain their brand name. A few of the recent developments in the global immunodiagnostics market are mentioned below:

In May 2023, Thermo Fisher Scientific announced that the US FDA had cleared its immunoassays, B·R·A·H·M·S PlGF plus KRYPTOR and B·R·A·H·M·S sFlt-1 KRYPTOR novel biomarkers. These immunoassays assess risks and clinical management of preeclampsia, a severe pregnancy complication.

In May 2022, Roche and The Global Fund to Fight AIDS, Tuberculosis and Malaria joined forces to build and strengthen diagnostic capacity and pandemic preparedness in low-and middle-income countries fighting against HIV and tuberculosis (TB).

In September 2022, Mindray launched the ToRCH Panel. With this panel, the company offers high-quality assays to meet different clinical needs. Mindray ToRCH kits support diverse sample types with less quality controls and sample volumes, which ensures great ease and convenience during clinical detection.

In May 2022, Thermo Fisher Scientific announced that the Phadia 2500+ series of instruments are available for autoimmune testing in the US. The family of high-capacity, intuitive lab instruments supplied by Thermo Fisher Scientific, the world leader in serving science, offers reliable and unparalleled high throughput for both allergy diagnostics and autoimmune testing.

In July 2022, Roche announced the launch of the Elecsys HCV Duo immunoassay in countries that accept the CE Mark. The Elecsys HCV Duo immunoassay enables a significantly earlier diagnosis of active HCV infection, making it possible to get patients appropriate care sooner to stop both the disease progression and transmission.

Browse key market insights spread across 270 pages with 166 list of tables & 98 list of figures from the report, “Immunodiagnostics Market Forecast to 2030 – COVID-19 Impact and Global Analysis by Product [Enzyme-Linked Immunosorbent Assays (ELISA), Chemiluminescence Immunoassays (CLIA), Radioimmunoassays (RIA), and Others], Clinical Indication (Infectious Diseases, Hepatitis+HIV, Endocrinology, Gastrointestinal, Metabolics, and Others), End User (Hospitals, Clinics, Diagnostic Laboratories, Academic & Research Institutes, and Others), and Geography” in detail along with the table of contents: https://www.theinsightpartners.com/reports/immunodiagnostics-market

Rising Focus on R&D Investment and Expansion by Key Players Will Likely Offer Opportunities for Global Immunodiagnostics Market Growth:
Research and development (R&D) has been the crucial part of the pharmaceutical business. It enables companies to develop new products with significant medical and commercial potential for various diagnostic applications. Due to the surging prevalence of infectious diseases, companies invest and generate huge revenues for expansion activities. During the COVID-19 pandemic, Thermo Fisher Scientific Inc. witnessed a 48% increase in the sales of its specialty diagnostics segment (sub-segmented into clinical diagnostics, immunodiagnostics, microbiology, transplant diagnostics, and healthcare market channel) in 2020. The segmental revenue of the company further increased in 2021 due to higher demand and sales of immunodiagnostic products used in COVID-19 treatment. In May 2021, PerkinElmer announced that it agreed to acquire UK-based in-vitro diagnostics company, Immunodiagnostic Systems (IDS), for ~US$ 155 million to expand the diagnostics business and immunodiagnostics division. Siemens Healthineers announced the investment of over US$ 32 million in its Glasgow Laboratory Diagnostics Manufacturing Facility in Newark, Delaware, in September 2021. The investment extending over 24 months enabled the company to add over 20 diagnostic tests in Delaware manufacturing capabilities. This initiative boosted the productivity of companies by maintaining stability across their diagnostic supply chains.

The extensive R&D for introducing innovative products opens several opportunities for small players and start-ups. The table below shows the annual support level for various research and disease categories based on contracts, grants, and other funding mechanisms used across the National Institutes of Health (NIH):

Infectious Diseases and Funding:

Research/Disease Areas (US$ Million) 2019 2020 2021 2022
Emerging Infectious Diseases US$ 2,950 US$ 4,867 US$ 5,069 US$ 4,318
Infectious Diseases US$ 6,313 US$ 8,301 US$ 8,599 US$ 8,019
Sexually Transmitted Infections US$ 354 US$ 394 US$ 404 US$ 419

Source: Annual Reports and The Insight Partners Analysis.

Manufacturers have also made a few key investments in the last few years. Cisco Systems, a global technology leader, invested US$ 225 million to combat the COVID-19 pandemic. This enabled the company to expand significantly and encourage new players to enter the market.

Buy Premium Copy of Immunodiagnostics Market Growth Report (2022-2030) at: https://www.theinsightpartners.com/buy/TIPRE00003722

Impact of COVID-19 Pandemic on Global Immunodiagnostics Market:
The medical industry across the globe witnessed a chaotic situation, with increased demand for clinical diagnostics and therapeutic systems in hospitals. With the increasing infection rate and the rising demand for diagnosis caused by the COVID-19 pandemic, the market experienced a positive impact across the world. Healthcare facilities, clinical laboratories, and pharmaceutical and biotech companies preferred advanced diagnostic techniques and systems to handle the burden of COVID-19.

The rising number of COVID-19 patients led to a positive impact on the market. In March 2021, Eurofins’ Clinical Enterprise, Inc. obtained an Emergency Use Authorization (EUA) from the US Food and Drug Administration (FDA) for a direct-to-consumer (DTC) version of its EmpowerDX COVID-19 Home Collection Kit. The Eurofins at-home COVID-19 nasal PCR kit is one of the first over-the-counter SARS-CoV-2 at-home test kits. Similarly, in March 2020, the US FDA issued Emergency Use Authorization (EUA) to Abbott for its fastest available molecular point-of-care test to detect novel coronavirus (COVID-19), which delivers positive results in approximately 5 minutes and negative results in around 13 minutes. Thus, the rise in product launches is supporting the immunodiagnostics market growth.

Go through further research published by The Insight Partners: (Purchase with 10% Instant Discount):

Veterinary Immunodiagnostic Device Market Forecast to 2028 – COVID-19 Impact and Global Analysis

Immuno-Oncology Drugs Market Forecast to 2028 – COVID-19 Impact and Global Analysis

Precision Diagnostics Market Forecast to 2028 – COVID-19 Impact and Global Analysis

In-Vitro Diagnostics Market Forecast to 2027 – Global Analysis

General Influenza Diagnostics Market Forecast to 2028 – COVID-19 Impact and Global Analysis

About Us:
The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.

Contact Us:
If you have any queries about this report or if you would like further information, please contact us:

Contact Person: Ankit Mathur
E-mail: [email protected] 
Phone: +1-646-491-9876
Press Release: https://www.theinsightpartners.com/pr/immunodiagnostics-market
Industry Research: https://www.biospace.com/employer/2735308/the-insight-partners/

Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. AfternoonHeadlines.com takes no editorial responsibility for the same.